Pipeline makes progress towards commercialization as robust demand for YSJA rabies vaccine continues
Gross margin increases to 80.3%; balance sheet remains strong
Read more at prnewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
Pipeline makes progress towards commercialization as robust demand for YSJA rabies vaccine continues
Gross margin increases to 80.3%; balance sheet remains strong
Read more at prnewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| YS | 1.0200 | +0.1129 | +12.45% |
| Ys Biopharma Co. Ltd | |||